Pilot study of chemopreventive effect of pioglitazone for colorectal cancer using aberrant crypt foci as a biomarker

ABSTRACT: Interventions: Oral administration of pioglitazone in 15mg daily. No administration of newly drug. Primary outcome(s): Observation of ACF using magnifying endoscopy Study Design: Parallel Randomized

DISEASE(S): Subjects With Aberrant Crypt Foci (acf)

PROVIDER: 2616758 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR